Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ArriVent BioPharma, Inc. (AVBP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ArriVent is a Nasdaq-listed, clinical-stage biopharmaceutical company, and its filings offer insight into the development of firmonertinib and its antibody-drug conjugate pipeline, as well as its capital structure and governance.
Through current reports on Form 8-K, ArriVent reports material events such as quarterly financial results, interim and final clinical data updates for firmonertinib in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer (NSCLC), public offerings of common stock and pre-funded warrants, and collaboration agreements. These filings also confirm that ArriVent’s common stock trades on The Nasdaq Stock Market LLC under the symbol AVBP and identify the company as an emerging growth company.
Investors can use this page to review how ArriVent describes its pivotal Phase 3 trials like FURVENT and ALPACCA, its Phase 1b FURTHER study, and regulatory milestones such as FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib. Filings may also discuss pipeline assets such as ARR-217 (MRG007), a CDH17-targeted ADC, and outline how equity offerings and cash resources are intended to support ongoing research and development.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on clinical trial status, financial condition, and corporate actions. Real-time updates from EDGAR, along with structured access to 8-Ks and other core filings, allow users to monitor changes in ArriVent’s development programs, financing activities, and governance without manually parsing every page.
ArriVent BioPharma, Inc. is the subject of an amended ownership report showing that Infinitum Cayman Master Ltd, together with Infinitum Asset Management LLC and Infinitum Partners GP, LLC, beneficially owns 4,123,923 shares of ArriVent common stock, representing 9.9% of the outstanding class.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of ArriVent. Voting and investment power over these shares is reported as sole, with no shared voting or dispositive power indicated.
ArriVent BioPharma, Inc. shareholder Hillhouse Investment Management, Ltd. reported beneficial ownership of 3,929,117 shares of ArriVent common stock, representing 9.5% of the company’s outstanding shares. This reflects Hillhouse’s position as of a reference base of 41,281,361 shares outstanding on November 7, 2025.
The shares are held through affiliated entities VI Holdings Limited, VIII Holdings Limited and ARVT Holdings Limited, for which Hillhouse is the sole management company. Hillhouse reports sole voting and dispositive power over all 3,929,117 shares, and the filing is an amendment to a prior Schedule 13G.
ArriVent BioPharma’s Chief Operating Officer, Robin LaChapelle, reported receiving a stock option award covering 130,000 shares of common stock. The option, granted on February 2, 2026, has an exercise price of $22.67 per share and expires on February 2, 2036.
The award vests as to 25% of the underlying shares on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on LaChapelle’s continued service with the company through each vesting date.
ArriVent BioPharma, Inc. reported that director and President of R&D Stuart Lutzker received a grant of 150,000 stock options to purchase common stock at an exercise price of $22.67 per share on February 2, 2026. These options expire on February 2, 2036.
The options vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on Lutzker’s continued service through each vesting date. Following this grant, he beneficially owns 150,000 derivative securities directly.
ArriVent BioPharma’s Chief Financial Officer Winston Kung received a stock option grant reported on this Form 4. On February 2, 2026, he was awarded an option to purchase 140,000 shares of common stock at an exercise price of $22.67 per share.
The option vests over time, with 25% of the underlying shares vesting on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on his continued service with the company through each vesting date. The option expires on February 2, 2036.
ArriVent BioPharma’s President and CEO, Zhengbin Yao, reported a new stock option grant. On February 2, 2026, he received an option to purchase 550,000 shares of common stock at an exercise price of $22.67 per share.
According to the filing, 25% of the option vests on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, he beneficially owns 550,000 derivative securities directly.
ArriVent BioPharma’s General Counsel, James Paul Kastenmayer, received a stock option grant reported on a Form 4. He was awarded options covering 130,000 shares of common stock at an exercise price of $22.67 per share.
The option was granted on February 2, 2026. The underlying shares vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on his continued service. Following this grant, he beneficially owns 130,000 stock options directly.
Hillhouse-affiliated investment entities reduced their stake in ArriVent BioPharma, Inc. A group of vehicles managed by Hillhouse Investment Management and HHLR Advisors reported selling 555,555 shares of ArriVent common stock on December 10, 2025 at $23.37 per share.
After this sale, the reporting group indirectly held 3,929,117 ArriVent shares through entities including HACF, L.P., VSUM VI Holdings Limited, VSUM VIII Holdings Limited and ARVT Holdings Limited. Hillhouse Investment Management, Ltd. and HHLR Advisors, Ltd. filed jointly as 10% owners and expressly disclaim beneficial ownership beyond their pecuniary interests.
The Vanguard Group reported beneficial ownership of 1,869,266 shares of ArriVent Biopharma Inc. common stock, representing 4.52% of the class as of 12/31/2025. Vanguard has no sole voting or dispositive power, with shared voting power over 242,661 shares and shared dispositive power over 1,869,266 shares.
Vanguard states that these securities are held in the ordinary course of business and not to change or influence control of ArriVent. Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, with no single client holding more than 5%. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Arrivent Biopharma Inc. common stock. BlackRock reports beneficial ownership of 2,319,341 shares, representing 5.6% of Arrivent’s outstanding common shares as of the event date.
The filing states that BlackRock has sole power to vote 2,279,791 shares and sole power to dispose of all 2,319,341 shares, with no shared voting or dispositive power. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arrivent Biopharma.